NCT05614869Withheld不适用
[Trial of device that is not approved or cleared by the U.S. FDA]
试验速览
- 阶段
- 不适用
- 状态
- Withheld
- 发起方
- [Redacted]
- 入组人数
- 353
研究概览
简要总结
The purpose of this study is to demonstrate substantial equivalence in terms of safety to support an indication change related to the usage of Prevena Therapy for up to 14 days. The enrolled subject will undergo 1 of 4 surgery types and be evaluated for up to 90 days.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 22 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject is at least 22 years of age on the date of informed consent
- •Subject can provide informed consent
- •Subject requires a surgical procedure for 1 of the 4 specialty treatment groups (ie, lower extremity orthopedic procedure, abdominal or C-section procedure, sternotomy, or vascular procedure)
- •Subject is willing and able to return for all scheduled study visits.
- •Subject has 1 or more of the following risk factors for post-surgical complications:
- •history of smoking
- •immune suppression or receiving drugs that can cause immune suppression (eg, steroids, chemotherapeutic medications, and/or antimetabolites)
- •high risk for malnutrition, as indicated by 2 or more of the following1:
- •insufficient energy intake
- •loss of muscle mass
- •loss of subcutaneous fat
- •localized or generalized fluid accumulation that may mask weight loss
- •diminished functional status as measured by hand-grip strength
- •has malnutrition, as determined by the investigator
- •neutropenia
- •cardiac, pulmonary, liver, or renal disease
- •history of previous surgery or radiation in the treatment area
- •Subject is pre-operatively assessed to undergo a procedure with a CDC Wound Classification of:
- •Class I (Clean): An uninfected operative wound in which no inflammation is encountered, and the respiratory, alimentary, genital, or uninfected urinary tract is not entered
- •Class II (Clean Contaminated): An operative wound in which the respiratory, alimentary, genital, or uninfected urinary tract are entered under controlled conditions and without unusual contamination
- •Subject has a closed post-surgical incision for which the anticipated duration of Prevena Therapy is more than 11 days
排除标准
- •Subject is female and, except in the case of C-section procedures, is pregnant or lactating prior to surgery
- •Subject has signs of an infection in the surgical area or has signs of a systemic infection at the time of surgery
- •Subject is a chronic opioid user, defined per the CDC guidelines as opioid use for > 3 months, at the time of enrollment
- •Subject has any of the following:
- •condition(s) that, in the opinion of the investigator, cause the patient to be an overall health risk that is unsuitable for the surgery
- •known sensitivity to the study product components (drape and/or dressing materials in direct contact with the closed incision or skin)
- •known sensitivity to silver
- •skin cancer localized at or in proximity to the incision site
- •intraoperative issue(s) that precludes the use of Prevena Therapy
- •Subject is preoperatively assessed to undergo a procedure with a CDC Wound Classification of:
- •Class III (Contaminated): Open, fresh, accidental wounds, and/or major breaks in sterile technique or gross spillage from the gastrointestinal tract
- •Class IV (Dirty-Infected): Old traumatic wounds with retained devitalized tissue and those that involve existing clinical infection or perforated viscera
- •Subject is enrolled in another interventional clinical study
研究者
相似试验
Unknown
不适用
The StUdy to Evaluate the Performance and safEty of the Novasight HybRid System Using Objective PeRformance CriteriaCoronary Artery DiseaseNCT04617899CardioNavi MedTech (Wuhan) Co., Ltd.120
已完成
不适用
Mini S Feasibility Study With Shockwave Medical Mini S Peripheral IVL SystemPeripheral Arterial DiseaseNCT05058456Shockwave Medical, Inc.35
终止
不适用
A Prospective, Multicenter, Single Arm Feasibility Study of the Safety and Performance of GRADION™ Hip Total Cartilage Replacement (TCR)™ in the Treatment of Degenerative Joint Disease of the HipDegenerative Joint Disease of the HipNCT01982266Biomimedica, Inc4
No Longer Available
不适用
Expanded Access of SotorasibNon Small-cell Lung CancerLocally Advanced Unresectable NSCLCLocally Advanced Metastatic NSCLCNCT04667234Amgen
Unknown
不适用
Maxx Orthopedics' PCK Revision TKA Study of Component SurvivorshipAseptic LooseningInfectionBone LossMCL - Medial Collateral Ligament Rupture of the KneePeriprosthetic FracturesNCT03312088Maxx Orthopedics Inc300